Loading
4 standard-of-care settings across 4 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers | FRα | Risk group |
|---|---|---|---|
| Early / localised | · | · | 1 |
| Advanced, first line | · | · | 1 |
| Second line | 1 | · | · |
| Third line and beyond | · | 1 | · |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Risk group | Very low / standard risk (PRETEXT I-III, resectable, AFP >100) | Upfront resection for PRETEXT I-II (COG) or cisplatin monotherapy ×4-6 with delayed resection (SIOPEL-3); sodium thiosulfate after each cisplatin dose for otoprotection. | PHITT / SIOPEL-3 (Lancet Oncol 2013); SIOPEL-6 (NEJM 2018) | 82 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Risk group | High risk (metastatic, AFP <100, PRETEXT IV, vascular involvement) | Cisplatin-doxorubicin (PLADO) or dose-dense cisplatin (SIOPEL-4), resection of primary and lung metastases; consider C5VD (COG). | SIOPEL-4; COG AHEP0731 | 86 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Unresectable after chemotherapy (POST-TEXT IV, central vascular involvement) | Orthotopic liver transplantation (5-year survival ~80%); early referral to a transplant centre. | SIOPEL guidance | 40 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| FRα | Relapsed/refractory | Irinotecan-based salvage, surgery for isolated recurrence, transplant if liver-confined; trials. | 90 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.